Along with the stunning progress of molecular technologies during the last decade, several new RT–PCR multiplexed platforms, including the CE-IVD IdyllaTM KRAS and NRAS-BRAF mutation test, have been developed to detect KRAS, NRAS, and BRAF mutations in colorectal cancer patients with significantly improved specificity, sensitivity (1–5%) and rapidity of analysis. This evidence concerns the gene BRAF and colorectal cancer.